Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9784474 | 0.87 | POLB (0.55) | ALDH1A1MAPTKDM4ECYP1A2KMT2A | |
| SCHEMBL10526068 | 0.86 | ALDH1A1 (0.56) | ALDH1A1MAPTKDM4ECYP1A2KMT2A | |
| SCHEMBL18183316 | 0.84 | ALDH1A1 (0.50) | ALDH1A1MAPTKDM4ECYP1A2KMT2A | |
| SCHEMBL29739340 | 0.84 | NPSR1 (0.51) | ALDH1A1MAPTKDM4ECYP1A2KMT2A | |
| SCHEMBL27485204 | 0.81 | KMT2A (0.51) | ALDH1A1MAPTKDM4ECYP1A2KMT2A | |
| SCHEMBL3984703 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4ECYP1A2KMT2A | |
| SCHEMBL11668327 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4ECYP1A2KMT2A | |
| SCHEMBL8809532 | 0.80 | PKM (0.48) | ALDH1A1MAPTKDM4ECYP1A2KMT2A | |
| SCHEMBL29739311 | 0.80 | NPC1 (0.51) | ALDH1A1MAPTKDM4ECYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL8808042 | 0.79 | PKM (0.47) | ALDH1A1MAPTKDM4ECYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
| US-7531576-B2 | Biphenyl derivatives | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1354871-B1 | BIPHENYL DERIVATIVES | POLA PHARMA INC (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20040048909-A1 | N-alkyl-N-(p-substituted-phenyl)benzylamine that is N-substituted with carbocyclic aminocarbonylalkylene, aminocarbonyl, or aminocarbonylaminosulfonyl; ACAT inhibitors; treating e.g.,hypercholesterolemia and atherosclerosis | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1354871-A1 | BIPHENYL DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-5420348-A | Enzyme inhibitors | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1995-05-30 | — | — | US | disclosed |
| EP-0447116-B1 | Urea derivatives, their production, and pharmaceutical compositions containing them | YAMANOUCHI PHARMA CO LTD (JP) | 1994-12-14 | — | — | EP | disclosed |
| US-5258405-A | Acetyl coenzyme A cholesterol acetyltransferase inhibitors for cardiovascular disorders and atherosclerosis and antilipemic agents | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1993-11-02 | — | — | US | disclosed |
| EP-0447116-A1 | Urea derivatives, their production, and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048909-A1 | N-alkyl-N-(p-substituted-phenyl)benzylamine that is N-substituted with carbocyclic aminocarbonylalkylene, aminocarbonyl, or aminocarbonylaminosulfonyl; ACAT inhibitors; treating e.g.,hypercholesterolemia and atherosclerosis | ACAT2, LCAT, NAT1 | ALDH1A1 1988/4885MAPT 2328/4885KDM4E 1512/4885 |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | ALDH1A1 3558/4885MAPT 1672/4885KDM4E 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.